{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:36Z","timestamp":1792525236830,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Diabetes Metab Disord"],"DOI":"10.1007\/s40200-026-02114-z","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:56:58Z","timestamp":1792267018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran"],"prefix":"10.1007","volume":"25","author":[{"given":"Negin","family":"Reiszadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Radmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Darvishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"2114_CR1","unstructured":"Purnell JQ. Definitions, classification, and epidemiology of obesity. 2015."},{"issue":"10","key":"2114_CR2","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/oby.24358","volume":"33","author":"J Liu","year":"2025","unstructured":"Liu J, et al. Projecting Global Trends and Inequalities in Adult Overweight and Obesity, 2023\u20132040: Findings From the NCD-RisC Database. Obesity. 2025;33(10):1955\u201367.","journal-title":"Obesity"},{"issue":"1","key":"2114_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s41043-023-00419-w","volume":"42","author":"B Abiri","year":"2023","unstructured":"Abiri B, et al. Prevalence of overweight and obesity among Iranian population: a systematic review and meta-analysis. J Health Popul Nutr. 2023;42(1):70.","journal-title":"J Health Popul Nutr"},{"key":"2114_CR4","unstructured":"Heart N, et al. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Heart, Lung, and Blood Institute. 1998."},{"issue":"1","key":"2114_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"GO Collaborators","year":"2017","unstructured":"Collaborators GO. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"2114_CR6","doi-asserted-by":"publisher","first-page":"e009773","DOI":"10.1136\/bmjgh-2022-009773","volume":"7","author":"A Okunogbe","year":"2022","unstructured":"Okunogbe A, et al. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ global health. 2022;7(9):e009773.","journal-title":"BMJ global health"},{"key":"2114_CR7","unstructured":"Tchang BG, et al. Pharmacologic treatment of overweight and obesity in adults. Endotext [Internet]. 2024."},{"key":"2114_CR8","unstructured":"Iran NF. o. \u0633\u0627\u0645\u0627\u0646\u0647 \u0627\u0637\u0644\u0627\u0639\u062a \u062f\u0627\u0631\u0648\u06cc\u06cc \u0627\u06cc\u0631\u0627\u0646. [cited 2025 5\/1\/2025]; Available from: https:\/\/irc.fda.gov.ir\/nfi"},{"issue":"6","key":"2114_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","volume":"138","author":"A Moiz","year":"2025","unstructured":"Moiz A, et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025;138(6):934\u201340.","journal-title":"Am J Med"},{"issue":"10","key":"2114_CR10","doi-asserted-by":"publisher","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","volume":"310","author":"SE Kanoski","year":"2016","unstructured":"Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885\u201395.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2114_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metabolism. 2021;23:5\u201329.","journal-title":"Diabetes Obes Metabolism"},{"issue":"14","key":"2114_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"10","key":"2114_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41366-023-01337-x","volume":"47","author":"YLL de Mesquita","year":"2023","unstructured":"de Mesquita YLL, et al. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes. 2023;47(10):883\u201392.","journal-title":"Int J Obes"},{"issue":"6","key":"2114_CR14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023;29(6):1500\u201310.","journal-title":"Nat Med"},{"issue":"3","key":"2114_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"2114_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JP Wilding","year":"2021","unstructured":"Wilding JP, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"2","key":"2114_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"key":"2114_CR18","doi-asserted-by":"crossref","unstructured":"Liu L et al. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine, 2025;79.","DOI":"10.1016\/j.eclinm.2024.103020"},{"issue":"11","key":"2114_CR19","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318.","journal-title":"Nat Med"},{"issue":"1","key":"2114_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"14","key":"2114_CR21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"3","key":"2114_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803\u201316.","journal-title":"Qual Life Res"},{"issue":"4","key":"2114_CR23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s11136-013-0557-8","volume":"23","author":"AE Rothberg","year":"2014","unstructured":"Rothberg AE, et al. The impact of weight loss on health-related quality-of-life: implications for cost-effectiveness analyses. Qual Life Res. 2014;23(4):1371\u20136.","journal-title":"Qual Life Res"},{"issue":"1","key":"2114_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12955-025-02378-8","volume":"23","author":"S Rezaei","year":"2025","unstructured":"Rezaei S. Population norms of health-related quality of life in Iran: findings from a national EQ-5D-5L study. Health Qual Life Outcomes. 2025;23(1):48.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2114_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1524-4733.2007.00260.x","volume":"11","author":"SL Dennett","year":"2008","unstructured":"Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health. 2008;11(3):478\u201386.","journal-title":"Value Health"},{"issue":"1","key":"2114_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3111\/13696998.2014.971158","volume":"18","author":"S Shingler","year":"2015","unstructured":"Shingler S, et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ. 2015;18(1):45\u201355.","journal-title":"J Med Econ"},{"key":"2114_CR27","unstructured":"UpToDate. [cited 2026 July 15]; Available from: https:\/\/www.uptodate.com\/"},{"key":"2114_CR28","unstructured":"International Monetary. Fund. Available from: https:\/\/www.imf.org\/external\/datamapper\/PPPEX@WEO\/OEMDC\/ADVEC\/WEOWORLD\/IRN"},{"issue":"1","key":"2114_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"10","key":"2114_CR30","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s11136-005-8027-6","volume":"14","author":"MA Kortt","year":"2005","unstructured":"Kortt MA, Clarke PM. Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res. 2005;14(10):2177\u201385.","journal-title":"Qual Life Res"},{"issue":"5","key":"2114_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.18553\/jmcp.2025.31.5.441","volume":"31","author":"L Liu","year":"2025","unstructured":"Liu L, et al. Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. J Managed Care Specialty Pharm. 2025;31(5):441\u201350.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"3","key":"2114_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s41669-025-00561-7","volume":"9","author":"P Papantoniou","year":"2025","unstructured":"Papantoniou P, Maniadakis N. Semaglutide 2.4\u00a0mg versus Liraglutide 3\u00a0mg for the treatment of obesity in Greece: a short-term cost-effectiveness analysis. PharmacoEconomics-Open. 2025;9(3):487\u201397.","journal-title":"PharmacoEconomics-Open"},{"key":"2114_CR33","unstructured":"Alshahawey M, et al. Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis. European Review for Medical & Pharmacological Sciences. 2024;28(9)."},{"issue":"2","key":"2114_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/endrev\/bnaf036","volume":"47","author":"JW Son","year":"2026","unstructured":"Son JW, et al. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocr Rev. 2026;47(2):159\u201377.","journal-title":"Endocr Rev"}],"container-title":["Journal of Diabetes &amp; Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-026-02114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40200-026-02114-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-026-02114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:03:05Z","timestamp":1792522985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40200-026-02114-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2114"],"URL":"https:\/\/doi.org\/10.1007\/s40200-026-02114-z","relation":{},"ISSN":["2251-6581"],"issn-type":[{"value":"2251-6581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Ethics Committee of Shahid Beheshti University of Medical Sciences (Approval No. IR.SBMU.PHNS.REC.1405.073). The study was conducted in accordance with relevant institutional guidelines and ethical standards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient-informed consent was not required because this study was based on published data and secondary sources, with no direct involvement of human participants or identifiable patient information.","order":2,"name":"Ethics","label":"Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"292"}}